News Agency
Men's Weekly

Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

  • Written by PR Newswire
Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
  • Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor approved for the treatment of r/r PTCL based on results from the multinational pivotal JACKPOT8B study.
  • Golidocitinib monotherapy demonstrated superior and durable clinical benefits and a favorable safety profile in r/r PTCL patients, compared with existing treatment options.

SHAN...

Read more: Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for the Treatment of...

How Family Lawyers Can Help Reduce Conflict During Separation

Separation is rarely straightforward, and the emotional weight it carries can make even practical decisions feel overwhelming. When communication between separating parties breaks down, disputes over property, finances and parenting arrangements can escalate quickly and become far more damaging than... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion